Welcome to our dedicated page for Zimmer Biomet SEC filings (Ticker: ZBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zimmer Biomet Holdings, Inc. filings document a public medical technology company with common stock listed under ZBH and several registered notes listed on the New York Stock Exchange. Recent 8-K reports cover quarterly and annual operating results, updated financial guidance, executive officer departures and interim finance leadership, debt securities, and completed acquisition activity.
The company's proxy and event filings disclose board and executive compensation matters, governance votes, Section 12(b) securities, material agreements, senior unsecured debt obligations, and exhibits tied to earnings releases. These records frame Zimmer Biomet's capital structure, leadership changes, shareholder governance and financial reporting for its orthopedic and musculoskeletal technology business.
Noor Jehanzeb reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. officer Noor Jehanzeb received a grant of 1,857 Restricted Stock Units, each representing a right to one share of common stock. These RSUs vest over three years in equal one-third installments starting on June 1, 2027. After this award, Jehanzeb holds 1,857 RSUs directly.
ZIMMER BIOMET HOLDINGS, INC. executive Yi Sang, Group President, Asia Pacific, reported selling a total of 5,000 shares of Common Stock in open-market transactions on May 29, 2026 at prices around $82.65 per share. After these sales, he continues to hold a substantial direct position of over 27,000 shares.
Fidelity Brokerage Services LLC submitted a Form 144 notice to sell 5,000 shares of Common Stock (aggregate value $413,216.42) for issuer with CUSIP 193462482 on 05/29/2026.
The filing lists prior acquisitions of Common Stock by the reporting account through restricted stock vesting and ESPP purchases on 03/06/2024 (1,308 shares), 06/28/2024 (136 shares), 12/31/2024 (80 shares) and 02/18/2025 (3,476 shares).
Zimmer Biomet Holdings, Inc. reported the results of its annual shareholder meeting held on May 22, 2026. Shareholders elected ten directors to one-year terms ending at the 2027 annual meeting, with each nominee receiving over 160 million votes in favor and substantial broker non-votes recorded.
Shareholders also ratified the Audit Committee’s appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for 2026, with 172,738,361 votes for and relatively few votes against or abstaining. On an advisory basis, they approved named executive officer compensation, with 160,066,066 votes for and 8,386,847 against. A shareholder proposal seeking an independent board chair was rejected, drawing 31,288,886 votes for and 137,043,058 against.
Farrell Michael J. reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings director Michael J. Farrell received new equity-based awards as part of his board compensation. On May 22, 2026, he was granted 1,517.274 Restricted Stock Units tied to common stock, bringing his total Restricted Stock Units to 13,757.
On the same date, he also received 875.350 Phantom Stock Units under the company’s Deferred Compensation Plan for Non-Employee Directors, increasing his phantom unit balance to 19,173.940. These units are generally settled in shares of common stock after his board service ends and are subject to mandatory deferral and dividend reinvestment features.
BERNARD BETSY J reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. director Betsy J. Bernard received equity-based compensation rather than trading shares in the market. She was granted 1,517.274 Restricted Stock Units and 875.350 Phantom Stock Units, each representing 1-for-1 rights to common stock.
The Restricted Stock Units are immediately 100% vested but must be deferred until the later of her board departure or three years after grant. The Phantom Stock Units, accrued under the Deferred Compensation Plan for Non-Employee Directors, will be settled in common shares within sixty days after her service as a director ends. Following these awards, her reported holdings rose to 24,506 Restricted Stock Units and 21,581.562 Phantom Stock Units.
Zimmer Biomet director Maria Teresa Hilado received new equity awards as part of her board compensation. On May 22, 2026, she was granted 1,517.274 Restricted Stock Units tied to common stock, bringing her total Restricted Stock Units holdings to 9,098. These units are immediately 100% vested but are subject to mandatory deferral until the later of her termination of service as a director or three years after the grant date.
She was also granted 875.350 Phantom Stock Units under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors, increasing her phantom stock balance to 12,594.369 units. The phantom units convert 1-for-1 into company common stock and are to be settled in shares within sixty days after she ceases serving as a director. The phantom balance includes 34.300 units accrued on April 30, 2026 through a dividend reinvestment provision, and some Restricted Stock Units granted in prior years remain subject to different mandatory deferral periods.
Shapiro Louis reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings director Louis Shapiro received new equity-based awards. On May 22, 2026, he was granted 1,517.274 Restricted Stock Units tied to common stock, increasing his total Restricted Stock Units to 3,991.063.
He was also granted 875.350 Phantom Stock Units under the Zimmer Biomet Deferred Compensation Plan for Non-Employee Directors, bringing his total phantom units to 3,544.416, including 7.812 units accrued through dividend reinvestment. Both award types represent deferred compensation, with phantom units and deferred RSUs to be settled in company common stock under the plan’s terms.
Kurdikar Devdatt reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings director Devdatt Kurdikar received new equity-based awards as part of director compensation. On May 22, 2026, he was granted 1,517.274 Restricted Stock Units, each representing one share of common stock, bringing his RSU holdings to 2,922.072 units. He also received 875.350 Phantom Stock Units under the Deferred Compensation Plan, increasing his phantom unit balance to 2,809.859 units. The phantom units are credited 1-for-1 in common stock and are to be settled in shares within sixty days after his service as a director ends. The RSUs are immediately 100% vested but are subject to mandatory deferral, generally until at least three years after grant and his termination of board service. These are compensation-related grants rather than open-market purchases or sales.
Kolli Sreelakshmi reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. director Sreelakshmi Kolli received equity-based compensation in the form of derivative awards. On May 22, 2026, Kolli was granted 1,517.274 Restricted Stock Units tied to Zimmer Biomet common stock, increasing her directly held RSUs to 6,875.
On the same date, she was also granted 875.350 Phantom Stock Units under the company’s Deferred Compensation Plan for Non-Employee Directors, bringing her phantom unit balance to 6,662.281. These phantom units are credited on a 1-for-1 basis with Zimmer Biomet common shares and are to be settled in shares of common stock within sixty days after her service as a director ends.
The RSUs are immediately 100% vested but are subject to mandatory deferral until the later of her termination of service as a director or three years after the grant date. Some units and RSUs referenced include amounts accumulated earlier through the plan’s dividend reinvestment and prior-year grants subject to different deferral periods.